9051 Mira Mesa Blvd, #910094
San Diego, CA 92191
Tel: 760-390-3989

Atosiban

Atosiban
HRM0005

Product Overview

Name	Atosiban

Description

Atosiban

Introduction

Atosiban is the first oxytocin antagonist to be specifically developed for the treatment of preterm labor. Atosiban has a specific mode of action, inhibiting oxytocin-induced uterine contractions by blocking oxytocin receptors in the uterus. Extensive clinical investigations have shown Atosiban to be at least as effective as current tocolytic agents. In addition, due to its novel and specific mode of action, Atosiban has a markedly improved maternal side effects profile compared with conventional therapies.

Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation

The Atosiban peptide was lyophilized with no additives.

Stability

Lyophilized Atosiban although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution Atosiban should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.

Purity

Greater than 98.0% as determined by analysis by RP-HPLC.

Solubility

It is recommended to reconstitute the lyophilized Atosiban in sterile 18MΩ-cm H2O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.

Precautions

Atosiban is for research use only and not for use in diagnostic or therapeutic procedures.